{"id":1509,"date":"2018-08-08T16:59:07","date_gmt":"2018-08-08T20:59:07","guid":{"rendered":"https:\/\/www.podiatrycanada.org\/?page_id=1509"},"modified":"2018-08-08T16:59:07","modified_gmt":"2018-08-08T20:59:07","slug":"advertising-criteria","status":"publish","type":"page","link":"https:\/\/cpma.thedev.ca\/?page_id=1509","title":{"rendered":"Advertising Criteria | Member discussion"},"content":{"rendered":"<p>[three_fourth]<\/p>\n<p>This is an open Member&#8217;s only discussion to debate our acceptance of sponsorship from Valeant Pharmaceuticals.<\/p>\n<div class=\"\"><\/div>\n<div class=\"\">\n<p>A few of the issues raised include their advertising practices for Jublia:<\/p>\n<\/div>\n<div class=\"\">\n<ul class=\"\">\n<li class=\"\">Ad campaigns which they do not mention that they are from Jublia.<\/li>\n<li class=\"\">Psychological shaming strategies in their ads.<\/li>\n<li class=\"\">Representations of efficacy which are per toe not per patient&#8230; so even a 15% success rate (vs placebo for complete cure) represents a failure rate of 85% . This is x2 if 2 toes are treated&#8230; i.e. 170% chance that 1 of two toes will not be cured.<\/li>\n<li class=\"\">I have attached an article about the economics of this medication.<\/li>\n<li class=\"\">Does this product fall below your standard of care?<\/li>\n<\/ul>\n<\/div>\n<div class=\"\"><\/div>\n<div class=\"\">\n<p>Concerns were also raised about their predatory pricing of other medications such as Syprine &#8211; a drug which used to be dollars a pill until Valeant purchased it and without any new research increased the price to $300,000 per year. This is not a type error:\u00a0 Many references include\u00a0<a class=\"\" href=\"https:\/\/www.bloomberg.com\/view\/articles\/2017-04-18\/valeant-drug-company-benevolence-and-the-silence-of-the-sick\" target=\"_blank\" rel=\"noopener\">https:\/\/www.bloomberg.com\/view\/articles\/2017-04-18\/valeant-drug-company-benevolence-and-the-silence-of-the-sick<\/a>.<\/p>\n<p>Netflix also has a one-hour documentary on Valeant. Dirty Money Season 1 Episode 3: &#8220;Drug Short&#8221;.<\/p>\n<p>Respectfully submitted by Dr. Adam Zanbilowicz, DPM (BC)<\/p>\n<\/div>\n<p>&nbsp;<\/p>\n<div class=\"\">\n<p>Please provide your comments, concerns, feedback on this issue. <strong>Please scroll down to add your comment.<\/strong><\/p>\n<\/div>\n<p>[\/three_fourth]<br \/>\n[one_fourth]<br \/>\n[do_widget id=widget_mfn_menu-13][do_widget id=widget_mfn_menu-12]<br \/>\n[\/one_fourth]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>[three_fourth] This is an open Member&#8217;s only discussion to debate our acceptance of sponsorship from Valeant Pharmaceuticals. A few of the issues raised include their advertising practices for Jublia: Ad campaigns which they do not mention that they are from Jublia. Psychological shaming strategies in their ads. Representations of efficacy which are per toe not per patient&#8230; so even a &hellip;<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":376,"menu_order":0,"comment_status":"open","ping_status":"closed","template":"","meta":{"footnotes":""},"_links":{"self":[{"href":"https:\/\/cpma.thedev.ca\/index.php?rest_route=\/wp\/v2\/pages\/1509"}],"collection":[{"href":"https:\/\/cpma.thedev.ca\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/cpma.thedev.ca\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/cpma.thedev.ca\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/cpma.thedev.ca\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1509"}],"version-history":[{"count":0,"href":"https:\/\/cpma.thedev.ca\/index.php?rest_route=\/wp\/v2\/pages\/1509\/revisions"}],"up":[{"embeddable":true,"href":"https:\/\/cpma.thedev.ca\/index.php?rest_route=\/wp\/v2\/pages\/376"}],"wp:attachment":[{"href":"https:\/\/cpma.thedev.ca\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1509"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}